Memantine-Merz
Memantine hydrochloride – NMDA receptor antagonist for moderate to severe Alzheimer’s disease
Quick Facts About Memantine-Merz
Key Takeaways About Memantine-Merz
- Treats moderate to severe Alzheimer's disease: Memantine-Merz helps slow cognitive and functional decline in patients with moderate to severe Alzheimer's dementia
- Gradual dose titration required: Treatment must start at 5 mg daily and increase by 5 mg each week over 3–4 weeks to reach the maintenance dose of 20 mg daily
- Can be combined with cholinesterase inhibitors: Memantine may be used alongside donepezil, rivastigmine, or galantamine for additional benefit
- Dose adjustment for kidney impairment: Patients with moderate to severe renal impairment require a reduced dose (maximum 10 mg daily)
- Generally well tolerated: The most common side effects are headache, drowsiness, dizziness, constipation, and elevated blood pressure, which are usually mild and transient
What Is Memantine-Merz and What Is It Used For?
Memantine-Merz contains the active substance memantine hydrochloride and belongs to a group of medicines known as NMDA receptor antagonists. It is used for the treatment of patients with moderate to severe Alzheimer's disease. It may help slow the worsening of memory loss, confusion, and problems with daily activities.
Alzheimer's disease is the most common form of dementia, affecting an estimated 55 million people worldwide according to the World Health Organization. The disease is characterized by a progressive decline in cognitive function, including memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. As the disease advances, patients become increasingly dependent on caregivers for daily activities such as dressing, eating, and personal hygiene.
The pathophysiology of Alzheimer's disease involves complex neurochemical changes in the brain, including the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. One important aspect of this process is the dysregulation of glutamate signaling. Glutamate is the brain's primary excitatory neurotransmitter and plays a vital role in learning and memory through activation of NMDA (N-methyl-D-aspartate) receptors. In Alzheimer's disease, chronically elevated glutamate levels lead to excessive stimulation of NMDA receptors, resulting in a phenomenon known as excitotoxicity, which damages and ultimately destroys neurons.
Memantine works as an uncompetitive, moderate-affinity, voltage-dependent NMDA receptor antagonist. Under normal physiological conditions, NMDA receptors are briefly activated during learning and memory formation. Memantine does not interfere with these normal signaling events. However, when glutamate levels are pathologically elevated – as in Alzheimer's disease – memantine blocks the NMDA receptors, preventing the sustained influx of calcium ions that leads to excitotoxic neuronal damage. This mechanism allows the drug to reduce the background "noise" of excessive glutamate signaling while preserving the "signal" of normal synaptic transmission required for cognition.
Memantine-Merz is approved for the treatment of moderate to severe Alzheimer's disease (typically defined as a Mini-Mental State Examination score of 3–14). It is not indicated for mild Alzheimer's disease or other forms of dementia, although research into its potential use in other neurodegenerative conditions is ongoing. Clinical trials, including the pivotal MEM-MD-02 study and subsequent Cochrane reviews, have demonstrated that memantine provides statistically significant benefits in cognition, global clinical impression, activities of daily living, and behavior in patients with moderate to severe Alzheimer's disease compared to placebo.
Memantine-Merz does not cure Alzheimer's disease and cannot reverse the underlying neurodegeneration. It is a symptomatic treatment that may slow the rate of decline. The benefits are generally modest but clinically meaningful, particularly for patients and their caregivers. Treatment should be initiated and supervised by a physician experienced in the diagnosis and management of Alzheimer's disease.
What Should You Know Before Taking Memantine-Merz?
Before starting Memantine-Merz, your doctor needs to know about your complete medical history, including any kidney problems, epilepsy or seizure history, heart conditions, and all other medications you are taking. Certain conditions require dose adjustments or close monitoring.
Contraindications
Memantine-Merz must not be used if you are allergic (hypersensitive) to memantine hydrochloride or to any of the other ingredients in the medication. Your doctor should also be informed of any previous allergic reactions to medications, particularly to other NMDA receptor antagonists such as amantadine.
There are no absolute contraindications to memantine beyond hypersensitivity to the active substance or excipients. However, several conditions require special caution. The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) both recommend careful clinical assessment before initiating treatment, and ongoing monitoring throughout therapy.
Warnings and Precautions
Memantine-Merz should be used with caution in patients with the following conditions:
- Epilepsy or history of convulsions: Memantine may lower the seizure threshold. Patients with a history of epilepsy or other predisposing factors for seizures should be closely monitored during treatment. In clinical trials, seizures occurred in approximately 0.2% of patients receiving memantine.
- Recent myocardial infarction: Patients who have had a heart attack within the past three months should be carefully evaluated before starting memantine, as there is limited clinical experience in this population.
- Congestive heart failure (NYHA Class III–IV): Memantine has not been extensively studied in patients with severe heart failure. Treatment should be initiated with caution and under close medical supervision.
- Uncontrolled hypertension: Some patients may experience elevated blood pressure during memantine treatment. Blood pressure should be monitored regularly.
- Renal impairment: Memantine is predominantly excreted by the kidneys. Patients with moderate renal impairment (creatinine clearance 30–49 mL/min) require dose reduction to 10 mg daily. In severe renal impairment (creatinine clearance 5–29 mL/min), the dose should be reduced to 10 mg daily and the patient closely monitored.
- Conditions that raise urinary pH: Alkaline urine (from renal tubular acidosis, severe urinary tract infections with Proteus bacteria, or strict vegetarian diets) can reduce the renal elimination of memantine, potentially leading to increased plasma levels and a higher risk of side effects.
Concurrent use of other NMDA antagonists (amantadine, ketamine, dextromethorphan) with memantine should be avoided, as the combination may increase the risk of central nervous system adverse effects including psychosis, hallucinations, and confusion. Inform your doctor about all medications you are currently taking, including over-the-counter cough medicines containing dextromethorphan.
Pregnancy and Breastfeeding
There are no adequate data on the use of memantine in pregnant women. Animal studies have shown some evidence of reduced fetal growth at doses similar to those used in humans. The potential risk for humans is unknown. Memantine-Merz should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus, and only after careful consideration by the treating physician.
It is not known whether memantine is excreted in human breast milk. Given the lipophilic nature of the molecule, excretion into breast milk is considered likely. Women taking Memantine-Merz should not breastfeed. If breastfeeding is desired, memantine treatment should be discontinued after discussion with the prescribing physician.
Memantine has no known effect on fertility in humans. Animal studies at therapeutic doses have not shown any adverse effects on fertility or reproductive performance.
How Does Memantine-Merz Interact with Other Drugs?
Memantine-Merz can interact with several types of medications, including other NMDA antagonists, dopaminergic agents, barbiturates, anticholinergics, and drugs that affect urinary pH. Your doctor and pharmacist should be informed of all medications you are taking to avoid potentially harmful interactions.
Drug interactions with memantine can be broadly categorized based on the mechanism of interaction. Pharmacodynamic interactions occur when co-administered drugs have additive or opposing effects at the same receptor systems. Pharmacokinetic interactions may occur when other drugs alter the absorption, distribution, metabolism, or excretion of memantine. Since memantine undergoes minimal hepatic metabolism (it is primarily renally excreted as unchanged drug), cytochrome P450-based interactions are rare, which is a clinical advantage compared to many other central nervous system medications.
Major Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Amantadine | Both are NMDA antagonists; additive CNS effects | Avoid combination – increased risk of psychosis, confusion, hallucinations |
| Ketamine | Both are NMDA antagonists; pharmacodynamic interaction | Avoid combination – increased CNS adverse effects |
| Dextromethorphan | NMDA antagonist found in many OTC cough medicines | Avoid combination – inform patients about OTC cough products |
| Sodium bicarbonate / carbonic anhydrase inhibitors | Alkalinize urine, reducing memantine renal clearance | Monitor for increased memantine side effects; dose adjustment may be needed |
Minor Interactions and Monitored Combinations
| Drug / Drug Class | Type of Interaction | Clinical Recommendation |
|---|---|---|
| Donepezil / Rivastigmine / Galantamine | Cholinesterase inhibitors; complementary mechanism | Safe to combine – commonly used together for added benefit |
| L-dopa / Dopaminergic agonists | Memantine may enhance dopaminergic effects | Monitor for increased dopaminergic side effects |
| Barbiturates / Neuroleptics | Potential reduction of their effects by memantine | Monitor therapeutic response; dose adjustment may be needed |
| Baclofen / Dantrolene | Potential modification of antispastic effects | Monitor and adjust doses as clinically indicated |
| Hydrochlorothiazide | Reduced renal clearance of hydrochlorothiazide | Monitor diuretic effect and electrolytes |
| Cimetidine / Ranitidine | Use the same renal cationic transport system | Potential for increased plasma levels of either drug; monitor |
| Warfarin | Isolated reports of increased INR | Monitor INR closely when starting or stopping memantine |
Importantly, clinical studies have shown no significant interaction between memantine and the cholinesterase inhibitors donepezil, rivastigmine, and galantamine. This is clinically relevant because combination therapy with a cholinesterase inhibitor and memantine is a widely used approach for managing moderate to severe Alzheimer's disease. The Tariot et al. (2004) landmark trial demonstrated that adding memantine to stable donepezil therapy provided additional benefits in cognition and daily functioning compared to donepezil alone.
What Is the Correct Dosage of Memantine-Merz?
The recommended maintenance dose of Memantine-Merz is 20 mg once daily. Treatment should be initiated at 5 mg per day and gradually increased by 5 mg per week over the first 3–4 weeks. This gradual titration helps minimize potential side effects. Dose adjustments are necessary for patients with kidney impairment.
Adults
Memantine-Merz treatment should be started and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. The diagnosis should be established according to current clinical guidelines (such as the NIA-AA or IWG criteria) before initiating treatment.
The recommended dose titration schedule for adults with normal renal function is as follows:
| Week | Daily Dose | Tablet(s) |
|---|---|---|
| Week 1 | 5 mg | One 5 mg tablet once daily |
| Week 2 | 10 mg | One 10 mg tablet once daily |
| Week 3 | 15 mg | One 15 mg tablet once daily |
| Week 4 onwards | 20 mg (maintenance) | One 20 mg tablet once daily |
Memantine-Merz tablets should be taken once daily at approximately the same time each day. They can be taken with or without food. The tablets should be swallowed whole with a glass of water. The minimum recommended interval between dose increases is one week to allow the body to adjust to each new dose level.
Children and Adolescents
Memantine-Merz is not recommended for use in children and adolescents under 18 years of age. Alzheimer's disease does not occur in this age group, and there is insufficient data on the safety and efficacy of memantine in pediatric populations for any indication. The European Medicines Agency has waived the obligation for the marketing authorization holder to submit studies with memantine in all subsets of the pediatric population for the treatment of Alzheimer's disease.
Elderly Patients
No dose adjustment is required based on age alone. As Memantine-Merz is specifically indicated for Alzheimer's disease, the vast majority of patients treated will be elderly (65 years and older). Clinical trials have included patients up to 93 years of age, and memantine was generally well tolerated across all age groups. However, elderly patients are more likely to have co-existing renal impairment, which may necessitate dose adjustment as described below.
Renal Impairment Dosing
Mild Renal Impairment (GFR 50–80 mL/min)
No dose adjustment required. Standard titration to 20 mg/day maintenance dose.
Moderate Renal Impairment (GFR 30–49 mL/min)
If tolerated after at least 7 days of treatment at 10 mg/day, the dose may be increased to 10 mg/day as the maintenance dose. Maximum dose: 10 mg/day.
Severe Renal Impairment (GFR 5–29 mL/min)
The daily dose should be 10 mg/day. Close monitoring is essential. The benefit-risk ratio should be regularly assessed in these patients.
Hepatic Impairment
No dose adjustment is required in patients with mild to moderate hepatic impairment (Child-Pugh A and B). Memantine undergoes minimal hepatic metabolism and is primarily excreted unchanged through the kidneys. There are no data available for patients with severe hepatic impairment (Child-Pugh C), and memantine is therefore not recommended in this population.
Missed Dose
If you forget to take a dose of Memantine-Merz, take it as soon as you remember, provided it is not close to the time for your next dose. Do not take a double dose to make up for a forgotten dose. If you miss several doses, contact your doctor or pharmacist for guidance on how to restart the medication, as a brief re-titration period may be advisable depending on how long treatment was interrupted.
Overdose
In case of suspected overdose, contact your local poison control center or emergency department immediately. Symptoms of overdose reported in clinical experience and the medical literature include restlessness, psychosis, visual hallucinations, drowsiness (somnolence), stupor, and loss of consciousness. In a documented case of a patient who took up to 400 mg of memantine, the patient recovered without permanent consequences after symptomatic treatment.
There is no specific antidote for memantine overdose. Treatment is symptomatic and supportive. Standard clinical measures to remove unabsorbed drug (such as gastric lavage, activated charcoal) may be considered. Due to memantine's long elimination half-life (60–100 hours), prolonged monitoring may be necessary. Enhanced elimination through acidification of urine is theoretically possible but should be weighed against the risk of complications.
What Are the Side Effects of Memantine-Merz?
Like all medicines, Memantine-Merz can cause side effects, although not everybody gets them. The most common side effects include headache, drowsiness, dizziness, constipation, and elevated blood pressure. Most side effects are mild to moderate in severity and tend to resolve as treatment continues.
Clinical trials enrolling over 1,900 patients treated with memantine and 1,400 patients treated with placebo have provided comprehensive safety data. Overall, the incidence of adverse events in memantine-treated patients was similar to that in the placebo group, reflecting the generally favorable tolerability profile of the drug. Post-marketing surveillance data from millions of patient-years of exposure have further confirmed the known safety profile without identifying significant new safety signals.
The following side effects have been organized by frequency according to the standard international classification used by the European Medicines Agency:
Common Side Effects
- Headache
- Drowsiness (somnolence)
- Dizziness
- Constipation
- Elevated blood pressure (hypertension)
- Shortness of breath (dyspnea)
Uncommon Side Effects
- Fatigue
- Fungal infections (mycosis)
- Confusion
- Hallucinations (mostly in severe dementia)
- Abnormal gait
- Heart failure
- Venous thrombosis / thromboembolism
- Vomiting
Rare Side Effects
- Seizures
- Psychotic reactions
- Pancreatitis
Very Rare / Post-Marketing Reports
- Hepatitis
- Agranulocytosis, leukopenia, pancytopenia, thrombocytopenia
- Stevens-Johnson syndrome
It is important to note that many of these side effects, particularly hallucinations and confusion, are also symptoms of Alzheimer's disease itself. In clinical trials, it can be difficult to distinguish drug-related adverse events from disease progression. The overall discontinuation rate due to adverse events in clinical trials was similar between memantine (7.4%) and placebo (7.7%), suggesting that memantine does not substantially increase the burden of side effects beyond what patients experience from their underlying condition.
Contact your doctor or seek emergency medical care immediately if you experience severe allergic reactions (difficulty breathing, swelling of face, lips, tongue, or throat), seizures, sudden severe headache, chest pain, signs of stroke (sudden weakness on one side, difficulty speaking, vision changes), or severe skin reactions (widespread rash with blistering). These are rare but potentially serious events that require immediate medical evaluation.
How Should You Store Memantine-Merz?
Store Memantine-Merz at room temperature below 25°C (77°F) in the original packaging to protect from moisture. Keep the medication out of the reach and sight of children. Do not use after the expiry date printed on the carton and blister.
Memantine-Merz film-coated tablets do not require any special storage conditions beyond normal room temperature. The tablets should be stored in their original blister packaging until use to protect them from moisture and light. Do not remove tablets from the blister strip in advance, as this may compromise their stability.
The expiry date refers to the last day of the month printed on the packaging. Do not use Memantine-Merz after this date, as the manufacturer cannot guarantee the potency, safety, or quality of the medication beyond the stated shelf life. If you have expired medication, do not dispose of it in household waste or wastewater. Return unused or expired medications to your pharmacy for safe disposal in accordance with local environmental regulations.
If you notice any change in the appearance of the tablets, such as discoloration, unusual odor, crumbling, or stickiness, do not take them and consult your pharmacist. These changes may indicate degradation of the product.
What Does Memantine-Merz Contain?
Each Memantine-Merz film-coated tablet contains memantine hydrochloride as the active substance, available in strengths of 5 mg, 10 mg, 15 mg, and 20 mg. The tablets also contain several inactive ingredients (excipients) that are necessary for the manufacturing process and drug stability.
The active substance in Memantine-Merz is memantine hydrochloride. Memantine hydrochloride is the salt form of memantine (chemically known as 1-amino-3,5-dimethyladamantane hydrochloride), which has a distinctive adamantane ring structure. The hydrochloride salt form is used because it provides good water solubility and bioavailability when administered orally.
The typical excipients (inactive ingredients) found in memantine film-coated tablets include:
- Tablet core: Microcrystalline cellulose, lactose monohydrate, colloidal anhydite silicon dioxide (colloidal silica), talc, and magnesium stearate
- Film coating: Methacrylic acid-ethyl acrylate copolymer, sodium laurilsulfate, polysorbate 80, talc, triacetin, and simethicone emulsion. Different tablet strengths may have different colored coatings to aid identification
Patients with known allergies to lactose or other excipients should inform their doctor or pharmacist before starting treatment. The amount of lactose in each tablet is generally very small but may be relevant for patients with severe lactose intolerance or galactose intolerance.
Each tablet strength has a distinctive appearance to help prevent medication errors:
- 5 mg tablets: White, film-coated, oblong tablets
- 10 mg tablets: Film-coated, oblong tablets (may be a pale yellow or other color depending on manufacturer)
- 15 mg tablets: Film-coated, oblong tablets with distinctive color
- 20 mg tablets: Film-coated, oblong tablets with distinctive color and markings
Frequently Asked Questions About Memantine-Merz
Memantine-Merz is used to treat moderate to severe Alzheimer's disease. It contains memantine hydrochloride, which works by blocking NMDA receptors in the brain. This reduces the harmful effects of excessive glutamate signaling that contributes to neuronal damage in Alzheimer's disease. It does not cure the disease but may help slow the decline in memory, thinking, daily functioning, and behavior. It is sometimes used in combination with cholinesterase inhibitors such as donepezil for enhanced benefit.
The most common side effects of Memantine-Merz include headache, drowsiness, dizziness, constipation, and elevated blood pressure. These are generally mild to moderate in severity and often improve as treatment continues. Uncommon side effects include confusion, hallucinations, fatigue, vomiting, and abnormal gait. If side effects are troublesome or persistent, consult your doctor, but do not stop taking the medication without medical advice.
Yes, Memantine-Merz can be safely combined with cholinesterase inhibitors including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl). In fact, combination therapy is a common and recommended approach for moderate to severe Alzheimer's disease. Research shows that the two drug classes work through complementary mechanisms and may provide additional cognitive and functional benefits when used together. Your doctor will determine if combination therapy is appropriate for your situation.
Memantine-Merz requires a gradual dose titration over 3–4 weeks to reach the maintenance dose of 20 mg daily. Clinical benefits may become apparent after 4 to 8 weeks at the full dose, although this varies between patients. The effects of memantine are often subtle and may be more noticeable to caregivers than to patients themselves. Benefits may include stabilization or slowed decline in cognition, daily activities, and behavioral symptoms rather than dramatic improvement.
Yes, dose adjustment is necessary for patients with impaired kidney function. Memantine is primarily excreted by the kidneys, so reduced kidney function can lead to higher drug levels in the blood. No adjustment is needed for mild kidney impairment (GFR 50–80 mL/min). For moderate impairment (GFR 30–49 mL/min), the maximum dose is 10 mg daily. For severe impairment (GFR 5–29 mL/min), the dose should be limited to 10 mg daily with close monitoring. Your doctor will assess your kidney function through blood tests before and during treatment.
All information is based on international medical guidelines and peer-reviewed research: European Medicines Agency (EMA) Summary of Product Characteristics for memantine, FDA Prescribing Information, NICE Technology Appraisal TA217, Cochrane Database systematic review on memantine for dementia (McShane et al., 2019), WHO Model List of Essential Medicines, and key clinical trials including the Tariot et al. (2004) study on combination therapy. All medical claims follow the GRADE evidence framework and represent evidence level 1A.
References
- European Medicines Agency (EMA). Summary of Product Characteristics: Memantine. Last updated 2024. Available from: www.ema.europa.eu
- McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019;3(3):CD003154. doi:10.1002/14651858.CD003154.pub6
- Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–324. doi:10.1001/jama.291.3.317
- National Institute for Health and Care Excellence (NICE). Technology Appraisal TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Updated June 2018.
- Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine. 2003;348(14):1333–1341. doi:10.1056/NEJMoa013128
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List, 2023. Memantine included for dementia management.
- Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Research & Therapy. 2014;6(4):37. doi:10.1186/alzrt269
- U.S. Food and Drug Administration (FDA). Prescribing Information: Namenda (memantine hydrochloride). Reference ID: 4866052.
- Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotoxicity Research. 2013;24(3):358–369. doi:10.1007/s12640-013-9398-z
- Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia. 2024;20(5). Available from: www.alz.org
Medical Editorial Team
This article has been written and reviewed by iMedic's medical editorial team, consisting of licensed physicians with specializations in neurology, geriatric medicine, and clinical pharmacology. Our team follows international guidelines from the WHO, EMA, FDA, and NICE to ensure all information meets the highest standards of medical accuracy and clinical relevance.
iMedic Medical Editorial Team – Specialists in neurology and clinical pharmacology with extensive experience in dementia care and drug information.
iMedic Medical Review Board – Independent panel of board-certified physicians who verify all clinical claims against current evidence and international guidelines.
All medical content follows the GRADE evidence framework. Clinical claims are supported by Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) wherever possible. This article was last fact-checked on .